



World Wide ADNI Update July 11, 2014

Total Number of FDG Scans by Group

Number of FDG Scans	Normal	SMC	EMCI	LMCI	AD	Total
1	119	104	165	158	138	684
2	133	0	141	74	25	373
3	6	0	1	18	17	42
4	13	0	0	16	58	87
5	33	0	0	41	0	74
6	15	0	0	49	0	64
7	19	0	0	29	0	48
8	5	0	0	26	0	31
9	0	0	0	1	0	1
Total	343	104	307	412	238	1404

Total Number of Florbetapir Scans by Group

Number of Florbetapir Scans	Normal	SMC	EMCI	LMCI	AD	Total
1	138	74	160	167	125	664
2	135	0	145	91	13	384
Total	273	74	305	258	138	1048


The last ADNI Subject will have his second scan by December 2015

By the end of 2014 there will be ~800 subjects with 2 scans

There are currently 5 subjects with 3 scans

By December 2014 there will be ~100 third scans


Florbetapir status by diagnosis




Baseline florbetapir cortical SUVR

Total N=1048

Florbetapir by APOE4 status



Florbetapir change



Total N=473

Florbetapir not increasing N=190 (18% APOE4+)

Florbetapir -Increasing N=79 (24% APOE4+)


Florbetapir + not increasing N=91 (60% APOE4+)

Florbetapir + Increasing N=113 (70% APOE4+)

Annual florbetapir change

Florbetapir cortical SUVR

Florbetapir change



Total N=473

Florbetapir not increasing N=190 (18% APOE4+)

Florbetapir -Increasing N=79 (24% APOE4+)

Florbetapir + not increasing N=91 (60% APOE4+)

Florbetapir + Increasing N=113 (70% APOE4+)

ADNI3: Time for Tau

Motivation:

Correlation with severity – outcome biomarker
Subject selection – "AD pathway"
Tau-targeted therapy


Currently 3 potential compounds PBB3 with [¹¹C] label [¹⁸F]T807 (AV-1451) and [¹⁸F]THK5117


2 ADNI Pilot Grants proposing AV-1451 DOD (funded), NIA Supplement (pending)


Normal Controls


[¹⁸F]-AV-1451

PIB DVR 1.02













PIB DVR 1.21













PIB DVR 1.02









Control Time-Activity Curve

